A Retrospective Study Assessing Serum Prostate Specific Antigen Levels in Patients with Prostate Lesions
Authors/Creators
- 1. Tutor, Department of Pathology, DMCH, Darbhanga, Bihar, India
- 2. HOD, Department of Pathology, DMCH, Darbhanga, Bihar, India
Description
Aim: The aim of the present study was to assess the serum prostate specific antigen levels in patients with prostate lesions. Methods: This was a retrospective record based study in which we retrieved all the prostatic specimens including Transurethral urethral resection of prostate (TURP) specimens and prostatic core biopsies, received at the Department of Pathology, DMCH, Darbhanga, Bihar, India over period of one year. Out of total 140 prostatic specimens received during the study period, total of 100 cases satisfied the inclusion criteria. Results: Out of total 100 cases, 86 (86%) were benign lesions which included 56 cases BPH alone, 24 cases of BPH with prostatitis while single 4 cases each for BPH with granulomatous prostatitis and basal cell hyperplasia. Mean PSA value for benign lesions was 6.57 ng/ml. There were 14 malignant lesions which included 12 cases of Prostatic adenocarcinomas (PCa) and a 2 cases of metastatic Transitonal cell carcinoma (TCC) of bladder. Mean PSA for PCa cases were 35.05 ng/ml. Single case of high grade prostatic intraepithelial neoplasia (HGPIN) also detected. The distribution of various prostatic lesions along with their PSA values was shown. Maximum prostatic lesions came under 0-4 PSA values. While maximum benign cases presented in seventh decade while maximum PCa cases presented in eighth decade of life in this study. Conclusion: We concluded that the most common prostatic lesions are benign predominantly BPH. PCa are the commonest malignancies. Common age group at the time of presentation of prostatic pathologies was 60-70 years. Elevated levels of PSA >20 ng/ml are commonly observed in PCa.
Abstract (English)
Aim: The aim of the present study was to assess the serum prostate specific antigen levels in patients with prostate lesions. Methods: This was a retrospective record based study in which we retrieved all the prostatic specimens including Transurethral urethral resection of prostate (TURP) specimens and prostatic core biopsies, received at the Department of Pathology, DMCH, Darbhanga, Bihar, India over period of one year. Out of total 140 prostatic specimens received during the study period, total of 100 cases satisfied the inclusion criteria. Results: Out of total 100 cases, 86 (86%) were benign lesions which included 56 cases BPH alone, 24 cases of BPH with prostatitis while single 4 cases each for BPH with granulomatous prostatitis and basal cell hyperplasia. Mean PSA value for benign lesions was 6.57 ng/ml. There were 14 malignant lesions which included 12 cases of Prostatic adenocarcinomas (PCa) and a 2 cases of metastatic Transitonal cell carcinoma (TCC) of bladder. Mean PSA for PCa cases were 35.05 ng/ml. Single case of high grade prostatic intraepithelial neoplasia (HGPIN) also detected. The distribution of various prostatic lesions along with their PSA values was shown. Maximum prostatic lesions came under 0-4 PSA values. While maximum benign cases presented in seventh decade while maximum PCa cases presented in eighth decade of life in this study. Conclusion: We concluded that the most common prostatic lesions are benign predominantly BPH. PCa are the commonest malignancies. Common age group at the time of presentation of prostatic pathologies was 60-70 years. Elevated levels of PSA >20 ng/ml are commonly observed in PCa.
Files
IJTPR,Vol14,Issue3,Article43.pdf
Files
(381.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:2814615ba62c6e5275fa243168e67a7c
|
381.5 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-03-14
Software
References
- 1. Kristal AR, Schenk JM, Song Y, Arnold KB, NeuhouserML, Goodman PJ, et al. Serum Steroid and Sex Hormone-Binding Globulin Concentrations and the Risk of Incident Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;168(12): 14 16–24. 2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter. NEng J Med. 2004;350 (2 2):2239–46. 3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86. 4. Anushree CN, Venkatesh K. Morphological spectrum of prostatic lesions - a clinicopathological study. Med Innov 2012; 1:49-54. 5. Wadgaonkar AR, Patil AA, Mahajan SV, Yengantiwar RP. Correlation of serum prostate specific antigen (PSA) level in various prostate pathology in elderly men. Int J Basic Appl Med Sci 2013; 3:274-81. 6. McNeal JE. The prostate and prostatic urethra: A morphologic synthesis. J Urol 1972; 107: 1008-16. 7. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145:907-23. 8. Bostwick DG. Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer. Am J Clin Pathol 1994;102: S31-7. 9. Rashid N, Dutta UC, Rahman ML, Hassan SW. Histomorphological spectrum of prostatic lesions and their correlation with serum prostate-specific antigen level. Int J Health Res Med Leg Pract 2020; 6:15-20. 10. Veliekovic LJ, Katic V, Tasic D, Kutlesic È, Dimov D, Ðoroevic B, et al. Prostate specific antigen (PSA) in neoplastic and hyperplastic prostate tissue. Arch Oncol 2001; 9:100-1. 11. Gurumurthy D, Maggad R, Patel S. Prostate carcinoma: correlation of histopathology with serum prostate specific antigen. Int J Sci Technol Soc 2015; 4:1-5. 12. Stimac G, Spajic B, Reljic A, Katusic J, Popovic A, Grubisic I, et al. Effect of histological inflammation on total and free serum prostatespecific antigen values in patients without clinically detectable prostate cancer. Korean J Urol 2014; 55:527-32. 13. Young GJ, Harrison S, Turner EL, Walsh EI, Oliver SE, Ben-Shlomo Y, et al. Prostatespecific antigen (PSA) testing of men in UK general practice: A 10-year longitudinal cohort study. BMJ Open 2017; 7:e017729. 14. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-69. 15. Macaluso PM. Epidemiology, prevention and screening for prostate cancer. Eur Urol. 1996; 29(2):49–53. 16. Brawer MK. Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer. The Augment for Eur Urol. 1996; 29(2):19–23. 17. Lakhey M, Ghimire R, Shrestha R, Bhatta AD. Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. Kathmandu University Medical J. 2010;8(2):158-63. 18. Vani BR, Kumar D, Sharath BN, Murthy VS, Geethamala K. A Comprehensive Study of Prostate Pathology in Correlation with Prostate-Specific Antigen Levels: An Indian Study. Clinc Cancer Investig J. 2015; 4:617-20. 19. Javed R, Suresh T, Shetty M. Study of morphological spectrum of prostatic lesions and its correlation with Ki-67 in a tertiary care hospital in rural South India. Al Ameen J Med Sci. 2016;9(3):175-82. 20. Jayapradeep DP, Prakash VB, Philipose TR, Pai MR. Histomorphological correlation of PSA levels in prostatic carcinoma. National J Lab Med. 2017; 6:28- 32. 21. Banerjee B, Iqbal BM, Kumar H, Kambale T, Bavikar R. Correlation between prostate specific antigen levels and various pathologies. J Med Soc. 2016; 30:172-5. 22. Wadgaonkar AR, Patil AA, Mahajan SV, Yengantiwar RP. Correlation of serum prostate specific antigen (PSA) level in various prostate pathology in elderly men. Int J Basic Appl Med Sci. 2013 May;3(2):274-81. 23. Bretton, P.R. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 1994; 87(7):720 – 723. 24. Richie J.P, Catalona W. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology1993; 42(4):365-74.